Next Article in Journal
Dual Role of p53 in Innate Antiviral Immunity
Next Article in Special Issue
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
Previous Article in Journal
Evasion of the Interferon-Mediated Antiviral Response by Filoviruses
Previous Article in Special Issue
Preliminary Report on HIV-1 Vaccine Preparedness in Nigeria: Advantages of Recruiting University Students
Review

The Development of an AIDS Mucosal Vaccine

by 1 and 1,2,*
1
AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
2
Department of Microbiology and Research Center of Infection and Immunology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
*
Author to whom correspondence should be addressed.
Viruses 2010, 2(1), 283-297; https://doi.org/10.3390/v2010283
Received: 12 October 2009 / Revised: 20 January 2010 / Accepted: 20 January 2010 / Published: 22 January 2010
(This article belongs to the Special Issue AIDS Vaccine)
It is well known that mucosal tissues contain the largest surface area of the human body and are the front line of natural host defense against various pathogens. In fact, more than 80% of infectious disease pathogens probably gain entry into the susceptible human hosts through open mucosal surfaces. Human immunodeficiency virus type one (HIV-1), a mainly sexually transmitted virus, also primarily targets the vaginal and gastrointestinal mucosa as entry sites for viral transmission, seeding, replication and amplification. Since HIV-1 establishes its early replication in vaginal or rectal mucosal tissues, the induction of sufficient mucosal immunity at the initial site of HIV-1 transmission becomes essential for a protective vaccine. However, despite the fact that current conventional vaccine strategies have remained unsuccessful in preventing HIV-1 infection, sufficient financial support and resources have yet to be given to develop a vaccine able to elicit protective mucosal immunity against sexual transmissions. Interestingly, Chinese ancestors invented variolation through intranasal administration about one thousand years ago, which led to the discovery of a successful smallpox vaccine and the final eradication of the disease. It is the hope for all mankind that the development of a mucosal AIDS vaccine will ultimately help control the AIDS pandemic. In order to discover an effective mucosal AIDS vaccine, it is necessary to have a deep understanding of mucosal immunology and to test various mucosal vaccination strategies. View Full-Text
Keywords: HIV-1; AIDS; vaccine; mucosal vaccination; MVTT HIV-1; AIDS; vaccine; mucosal vaccination; MVTT
MDPI and ACS Style

Tang, X.; Chen, Z. The Development of an AIDS Mucosal Vaccine. Viruses 2010, 2, 283-297. https://doi.org/10.3390/v2010283

AMA Style

Tang X, Chen Z. The Development of an AIDS Mucosal Vaccine. Viruses. 2010; 2(1):283-297. https://doi.org/10.3390/v2010283

Chicago/Turabian Style

Tang, Xian, and Zhiwei Chen. 2010. "The Development of an AIDS Mucosal Vaccine" Viruses 2, no. 1: 283-297. https://doi.org/10.3390/v2010283

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop